
LeMaitre Vascular (LMAT) Stock Forecast & Price Target
LeMaitre Vascular (LMAT) Analyst Ratings
Bulls say
LeMaitre Vascular is in a strong financial position with $200 million in net cash and strong cash flow dynamics, providing potential for continued external growth in assets. Additionally, their pricing power, expansions in international markets, and growing salesforce also contribute to a positive outlook. With consistent double-digit organic top line growth, margin expansion, and strong cash flow, we believe LMAT deserves a premium valuation and would recommend buying shares during any potential dips.
Bears say
LeMaitre Vascular is projected to continue delivering solid financial results with double-digit organic revenue growth and increased EPS guidance, driven by strong sales performance in its international markets and the potential for growth within its medical device products such as Artegraft and RestoreFlow. However, potential headwinds in the pricing environment and slower than expected unit volume growth could impact the company's overall revenue growth in the short term. Additionally, the company's target of 170-180 sales representatives by 2026 may be difficult to achieve, potentially limiting future sales growth.
This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.
LeMaitre Vascular (LMAT) Analyst Forecast & Price Prediction
Start investing in LeMaitre Vascular (LMAT)
Order type
Buy in
Order amount
Est. shares
0 shares